Drug Armamentarium for Alopecia Areata

Alopecia areata (AA) is an autoimmune condition causing nonscarring hair loss on the scalp and/or body, affecting 1-2% of people of all ages and leading to significant emotional and psychological stress. Despite various therapeutic options, including corticosteroids, JAK inhibitors, and minoxidil, none are curative or preventive, and treatment plans are tailored to the patient's age and disease extent. The global market for alopecia treatments was valued at $2.54 billion in 2018 and was expected to reach $3.98 billion by 2025, growing at a CAGR of 5.80%.